论文信息 - Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.

Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.

Lipoprotein lipase (LPL) deficiency is a monogenetic disorder that underlies persistently elevated triglyceride (TG) levels and consequently predisposes patients to potentially life-threatening pancreatitis. In view of the absence of adequate therapy, we developed a gene replacement strategy to lower TG levels in these patients.1 This report summarizes the data of a first clinical trial (CT-AMT-010-01) in LPL-deficient individuals after intramuscular administration of a viral vector. In a 3-month open-label study, LPLS447X-adeno-associated virus subtype 1(AAV1) vector1,2 was injected in the leg musculature of 8 LPL-deficient patients at a dose of 1×1011 (n=4) or 3×1011 (n=4) genome copies per kilogram body weight (40 and 60 …

[1] Marcela V Maus,et al. CD8+ T-cell responses to adeno-associated virus capsid in humans , 2007, Nature Medicine.

[2] M. Hayden,et al. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. , 2006, Human gene therapy.

[3] M. Hayden,et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. , 2005, Human gene therapy.

[4] H. Venema,et al. Dixon Quantitative Chemical Shift MRI for Bone Marrow Evaluation in the Lumbar Spine: A Reproducibility Study in Healthy Volunteers , 2001, Journal of computer assisted tomography.